ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Longitudinal changes in bone mineral density among adults with cystic fibrosis: a systematic review and meta-analysis.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundImproved survival in cystic fibrosis (CF) has increased the burden of cystic fibrosis-related bone disease (CFBD), yet the natural history of bone mineral density (BMD) decline remains poorly defined. We conducted a systematic review and meta-analysis (PROSPERO: CRD420251091118) to quantify longitudinal BMD changes in adults with CF.
methodsMEDLINE, Embase, Cochrane, and PubMed were searched through March 22, 2025 for observational studies and control arms of randomized trials reporting ≥2 dual-energy X-ray absorptiometry (DXA) scans ≥1 year apart in adults not receiving osteoporosis therapy; post-lung transplant DXAs were excluded. The primary outcome was annual percent change in BMD at the lumbar spine (LS) and femoral neck (FN). Random-effects models were used; heterogeneity was assessed with I².
resultsTwelve studies (n = 811; mean age 21-31 years; mean follow-up 24 months) were included, with 10 contributing to meta-analysis. Pooled annual BMD change was -0.28%/year (95% CI: -0.56, -0.01) at the LS and -0.90%/year (95% CI: -1.29, -0.52) at the FN. Heterogeneity was low to moderate (I² = 28.7% LS; 44.5% FN). Methodological quality was generally high, though confounding and incomplete follow-up were common. All studies predated widespread CFTR modulator use.
conclusionsAdults with CF experience progressive BMD loss, particularly at the FN, where the observed rate exceeded that expected for age. These findings support enhanced bone health strategies and highlight the need to evaluate CFTR modulator effects, fracture risk, and optimal monitoring in the modern treatment era.
Indexed as
Identifiers
42909486What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.